

PAINCHEK INVESTOR WEBINAR – QUARTERLY UPDATE AND MEET THE NEW TEAM

PainChek Limited (ASX: PCK) (“PainChek” or “the Company”) is pleased to invite shareholders and investors to an investor webinar on Monday, 10 August 2026 at 11.00 a.m. AEST.

The webinar will provide an update on PainChek’s June quarter performance, recent operational progress and leadership transition.

The June quarter delivered continued growth across the Company’s key operating measures, including:

- Implemented annual recurring revenue increased 5.9% to \$4.46 million;
- Implemented licences increased to 90,198;
- Customer receipts increased 27% quarter-on-quarter to \$1.28 million;
- Active customer sites reached 1,990;
- Cumulative PainChek assessments increased to 21.38 million; and
- Commercial deployments commenced in the United States.

The webinar will also provide investors with an opportunity to hear from PainChek’s leadership team, including:

- Lil Bianchi - Non-Executive Chair;
- Andy Hoggan - Interim Chief Executive Officer and Chief Operating Officer;
- Karen Holzberger - Incoming Chief Executive Officer; and
- David Allsopp - General Manager and Head of Business Development, North America.

The team will discuss the quarterly results, PainChek’s commercial priorities across Australia, the United Kingdom and North America, and the Company’s plans for its next phase of growth.

The presentation will be followed by a live question-and-answer session. Questions may be submitted when registering or during the webinar.

Webinar details

Date: Monday, 10 August 2026

Time: 11.00am AEST

Registration: [Register for the PainChek Investor Webinar](#)

A recording of the webinar will be made available following the event.

This announcement has been authorised for release by the Board of PainChek Limited.

ENDS

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

David Tasker
Chapter One Advisors
dtasker@chapteroneadvisors.com.au
+61 433 112 936

About PainChek

[PainChek®](#) is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, the United Kingdom and most recently FDA De Novo clearance in the United States.

PainChek® has contracts with over 2,000 aged care facilities, with more than 20,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

PainChek® is setting a new benchmark for pain assessment. Being the first TGA-approved and FDA-cleared medical device for pain assessment, PainChek® combines AI and Human Intelligence to detect pain in people who cannot reliably self-report.

For more information, visit: <https://painchek.com>